GPNX
NOTIFICATION PROCESSED BY IB
01/12/2024
Back to search
Official data from USPTO
BRYPEMDI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
01/12/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
12/19/2022
Registration date
11/21/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/21/2023
Last transaction
11/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
DE
Examiner
SMITH, BRIDGETT G
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Boehringer Ingelheim International GmbH
Representatives
Boehringer Ingelheim Corporate Center GmbH
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism, and of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell-based immune therapeutics for treatment cancer, for treatment of immunological diseases and treatment of infectious diseases
Publications
History of USPTO decisions and trademark events.
16 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/22/2023
FIMP
FINAL DISPOSITION PROCESSED
12/22/2023
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
12/21/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/21/2023
GPNX
NOTIFICATION PROCESSED BY IB
09/18/2023
PUBO
PUBLISHED FOR OPPOSITION
09/05/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/30/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/30/2023
NPUB
NOTICE OF PUBLICATION
08/16/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/31/2023
DOCK
ASSIGNED TO EXAMINER
07/30/2023
MAFR
APPLICATION FILING RECEIPT MAILED
02/18/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/14/2023
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
02/13/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/09/2023
Continuous trademark protection
Get notified about every new filing that threatens BRYPEMDI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.